EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the following upcoming conferences:

• H.C. Wainwright 24th Annual Global Investment ConferenceForum: Corporate PresentationDate: Monday, September 12, 2022Time: 7:00 a.m. ET

• Baird 2022 Global Healthcare ConferenceForum: Corporate PresentationDate: Wednesday, September 14, 2022Time: 1:25 p.m. ET

• Guggenheim Nantucket Therapeutics ConferenceForum: Fireside ChatDate: Thursday, September 29, 2022Time: 10:30 a.m. ET

• Benzinga Retail Conference (Virtual)Forum: Fireside ChatDate: Friday, September 30, 2022Time: 11:40 a.m. ET

A webcast and subsequent archived replay of the corporate presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Investors:

Christina TartagliaStern IRDirect: 212-698-8700[email protected]

Media Contact

Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499[email protected]

Source: EyePoint Pharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tungsten Tripled in 2026 and the U.S. Still Mines None of It
• Implantica's Capital Markets Day webcast available on demand
• Masan High-Tech Materials: How a Vietnamese Company Is Building a Role in Global Strategic Materials Supply Chains